Leukemia, Acute Myeloid disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

AML MCID: LKM061 MIFTS: 82	Leukemia, Acute Myeloid (AML) Categories: Blood diseases, Cancer diseases, Genetic diseases, Immune diseases, Rare diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Leukemia, Acute Myeloid

MalaCards integrated aliases for Leukemia, Acute Myeloid:

Name: Leukemia, Acute Myeloid ⁵⁷ ³⁶

Acute Myeloid Leukemia ¹¹ ¹⁹ ⁵⁸ ⁷⁵ ⁷³ ²⁸ ⁵ ⁴¹ ¹⁴ ¹⁶

Leukemia, Acute Myelogenous ⁵⁷ ⁷³ ¹² ³⁸

Acute Myelogenous Leukemia ¹¹ ¹⁹ ⁵⁸ ⁷⁵

Leukemia, Acute Myeloid, Susceptibility to ⁵⁷ ²⁸ ⁵

Acute Myeloblastic Leukemia ¹¹ ⁷⁵ ⁷³

Aml ⁵⁷ ⁵⁸ ⁷³

Therapy Related Acute Myeloid Leukemia and Myelodysplastic Syndrome ⁵⁸ ²⁸

Leukemia, Acute Myeloid, Reduced Survival in, Somatic ⁵⁷ ⁵

Leukemia, Myelocytic, Acute ¹¹ ⁷¹

Acute Myelocytic Leukemia ⁷⁵ ⁷³

Acute Myeloid Leukaemia ¹¹ ¹⁴

Secondary Aml ⁵⁸ ⁵³

Acute Myeloid Leukaemia with Multilineage Dysplasia Without Mention of Remission ³³

Acute Myeloid Leukaemia with Myelodysplasia-Related Features ³³

Acute Myeloblastic Leukaemia with Multilineage Dysplasia ³³

Acute Myeloid Leukemia with Cebpa Somatic Mutations ⁵⁸

Therapy-Related Aml and Myelodysplastic Syndrome ⁵⁸

Pure Familial Acute Myeloid Leukemia ⁵⁸

Acute Myeloid Leukemia, Secondary ⁷⁵

Leukemia, Acute Myeloid, Somatic ⁵⁷

Aml with Cebpa Somatic Mutations ⁵⁸

Inherited Acute Myeloid Leukemia ⁵⁸

Secondary Acute Myeloid Leukemia ⁵⁸

Acute Non-Lymphoblastic Leukemia ⁷³

Acute Myeloid Leukemia, Somatic ⁵⁷

Acute Undifferentiated Leukemia ⁷¹

Acute Non-Lymphocytic Leukemia ⁷³

Acute Myeloblastic Leukaemia ¹¹

Aml - Acute Myeloid Leukemia ¹¹

Acute Myelogenous Leukaemia ¹¹

Acute Biphenotypic Leukemia ⁷¹

Pure Familial Aml ⁵⁸

Inherited Aml ⁵⁸

Familial Aml ⁵⁸

Characteristics:

Inheritance:

Autosomal dominant ⁵⁷

Prevelance:

Acute Myeloid Leukemia: 1-9/100000 (Worldwide, Europe, France, Denmark, United States) 1-5/10000 (Europe, Europe) ⁵⁸

Therapy Related Acute Myeloid Leukemia and Myelodysplastic Syndrome: <1/1000000 (Europe) ⁵⁸

Age Of Onset:

Acute Myeloid Leukemia: All ages ⁵⁸

Therapy Related Acute Myeloid Leukemia and Myelodysplastic Syndrome: All ages ⁵⁸

OMIM®:

⁵⁷ (Updated 08-Dec-2022)

Miscellaneous:
evidence of anticipation
mean onset age 57 years, 32 years and 13 years in successive generations
many genes with somatic mutation

Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases Cancer diseases
Anatomical: Blood diseases Immune diseases

See all MalaCards categories (disease lists)

ICD10: ³¹ ³²

Neoplasms

Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue

Myeloid leukaemia

Acute myeloblastic leukaemia [AML]

Acute myeloid leukaemia with 11q23-abnormality

Acute myeloid leukaemia with multilineage dysplasia

ICD11: ³³

Neoplasms

Neoplasms of haematopoietic or lymphoid tissues

Acute myeloid leukaemias and related precursor neoplasms

Acute myeloid leukaemia with myelodysplasia-related changes

Acute myeloid leukaemia with recurrent genetic abnormalities

Acute myeloid leukaemia, not elsewhere classified by criteria of other types

Acute myeloid leukaemia with maturation

Acute myeloid leukaemia with minimal differentiation

Acute myeloid leukaemia without maturation

Acute myeloid leukaemia, unspecified

Therapy-related myeloid neoplasms

Orphanet: ⁵⁸

Rare haematological diseases

External Ids:

Disease Ontology ¹¹ DOID:9119

OMIM® ⁵⁷ 601626

ICD9CM ³⁴ 205.0

MeSH ⁴³ D015470

NCIt ⁴⁹ C3171

SNOMED-CT ⁶⁸ 17788007

ICD10 ³¹ C92.0 C92.6 C92.8

MESH via Orphanet ⁴⁴ D015470

ICD10 via Orphanet ³² C92.0

UMLS via Orphanet ⁷² C0023467 C1292776 C1879321

Orphanet ⁵⁸ ORPHA319465 ORPHA319480 ORPHA519 more

MedGen ⁴⁰ C0023467 C3275959

SNOMED-CT via HPO ⁶⁹ 413443009 91861009

EFO ¹⁶ EFO_0000222

ICD11 ³³ 1235412948 1430965006 1468530237 more

UMLS ⁷¹ C0023464 C0023467 C0280141

Sources

Summaries for Leukemia, Acute Myeloid

MedlinePlus: ⁴¹ What is leukemia? Leukemia is a term for cancers of the blood cells. Leukemia starts in blood-forming tissues such as the bone marrow. Your bone marrow makes the cells which will develop into white blood cells, red blood cells, and platelets. Each type of cell has a different job: White blood cells help your body fight infection Red blood cells deliver oxygen from your lungs to your tissues and organs Platelets help form clots to stop bleeding When you have leukemia, your bone marrow makes large numbers of abnormal cells. This problem most often happens with white blood cells. These abnormal cells build up in your bone marrow and blood. They crowd out the healthy blood cells and make it hard for your cells and blood to do their work. What is acute myeloid leukemia (AML)? Acute myeloid leukemia (AML) is a type of acute leukemia. "Acute" means that the leukemia usually gets worse quickly if it's not treated. In AML, the bone marrow makes abnormal myeloblasts (a type of white blood cell), red blood cells, or platelets. When the abnormal cells crowd out the healthy cells, it can lead to infection, anemia, and easy bleeding. The abnormal cells can also spread outside the blood to other parts of the body. There are several different subtypes of AML. The subtypes are based on how developed the cancer cells are when you get your diagnosis and how different they are from normal cells. What causes acute myeloid leukemia (AML)? AML happens when there are changes in the genetic material (DNA) in bone marrow cells. The cause of these genetic changes is unknown. However, there are certain factors that raise your risk of AML. Who is at risk for acute myeloid leukemia (AML)? The factors that raise your risk of AML include: Being male Smoking, especially after age 60 Having had chemotherapy or radiation therapy Treatment for acute lymphoblastic leukemia (ALL) as a child Exposure to the chemical benzene A history of another blood disorder such as myelodysplastic syndrome What are the symptoms of acute myeloid leukemia (AML)? The signs and symptoms of AML include: Fever Shortness of breath Easy bruising or bleeding Petechiae, which are tiny red dots under the skin. They are caused by bleeding. Weakness or feeling tired Weight loss or loss of appetite Bone or joint pain, if the abnormal cells build up near or inside the bones How is acute myeloid leukemia (AML) diagnosed? Your health care provider may use many tools to diagnose AML and figure out which subtype you have: A physical exam A medical history Blood tests, such as a complete blood count (CBC) and blood smear Bone marrow tests. There are two main types - bone marrow aspiration and bone marrow biopsy. Both tests involve removing a sample of bone marrow and bone. The samples are sent to a lab for testing. Genetic tests to look for gene and chromosome changes If you are diagnosed with AML, you may have additional tests to see whether the cancer has spread. These include imaging tests and a lumbar puncture, which is a procedure to collect and test cerebrospinal fluid (CSF). What are the treatments for acute myeloid leukemia (AML)? Treatments for AML include: Chemotherapy Radiation therapy Chemotherapy with stem cell transplant Other anticancer medicines Which treatment you get often depends on which subtype of AML you have. Treatment is usually done in two phases: The goal of the first phase is to kill the leukemia cells in the blood and bone marrow. This puts the leukemia into remission. Remission means that the signs and symptoms of cancer are reduced or have disappeared. The second phase is known as post-remission therapy. Its goal is to prevent a relapse (return) of the cancer. It involves killing any remaining leukemia cells that may not be active but could begin to regrow. NIH: National Cancer Institute

MalaCards based summary: Leukemia, Acute Myeloid, also known as acute myeloid leukemia, is related to acute megakaryocytic leukemia and acute myeloid leukemia with bcr-abl1, and has symptoms including angina pectoris, chest pain and edema. An important gene associated with Leukemia, Acute Myeloid is CEBPA (CCAAT Enhancer Binding Protein Alpha), and among its related pathways/superpathways are Disease and PI3K-Akt signaling pathway. The drugs Nicotine and Cytarabine have been mentioned in the context of this disorder. Affiliated tissues include Blood, and related phenotypes are acute myeloid leukemia and Reduced mammosphere formation

Orphanet ⁵⁸ Inherited acute myeloid leukemia: Inherited acute myeloid leukemia (AML) is a rare, malignant hematopologic disease characterized by clonal proliferation of myeloid blasts, primarily involving the bone marrow, in association with congenital disorders (e.g. Fanconi anemia, dyskeratosis congenita, Bloom syndrome, Down syndrome, congenital neutropenia, neurofibromatosis, etc.) and genetic defects predisposing to AML. Patients present with signs and symptoms related to ineffective hematopoesis (fatigue, bleeding and bruising, recurrent infections, bone pain) and/or extramedullary site involvement (gingivitis, splenomegaly, etc.). Depending on the underlying genetic defect, there may be additional cancer risks and other health problems present.

Acute myeloid leukemia with cebpa somatic mutations: A subtype of acute myeloid leukemia with recurrent genetic abnormalities, characterized by clonal proliferation of myeloid blasts harboring somatic mutations of the CEBPA gene in the bone marrow, blood and, rarely, other tissues. It can present with anemia, thrombocytopenia, and other nonspecific symptoms related to ineffective hematopoesis (fatigue, bleeding and bruising, recurrent infections, bone pain) and/or extramedullary site involvement (gingivitis, splenomegaly).

Acute myeloid leukemia: A group of neoplasms arising from precursor cells committed to the myeloid cell-line differentiation. All of them are characterized by clonal expansion of myeloid blasts. They manifest by fever, pallor, anemia, hemorrhages and recurrent infections.

GARD: ¹⁹ Acute myeloid leukemia (AML) is a cancer that affects the blood and bone marrow. Conditions are generally called "acute" when they develop quickly and have an aggressive course. The signs and symptoms of AML vary but may include easy bruising; bone pain or tenderness; fatigue; fever; frequent nosebleeds; bleeding from the gums; shortness of breath; and/or weightloss. AML is one of the most common types of leukemia among adults and is rarely diagnosed in people under age 40. There are many potential causes of AML such as certain blood disorders, inherited syndromes, environmental exposures, and drug exposures; however, most people who develop AML have no identifiable risk factor.

UniProtKB/Swiss-Prot: ⁷³ A subtype of acute leukemia, a cancer of the white blood cells. AML is a malignant disease of bone marrow characterized by maturational arrest of hematopoietic precursors at an early stage of development. Clonal expansion of myeloid blasts occurs in bone marrow, blood, and other tissue. Myelogenous leukemias develop from changes in cells that normally produce neutrophils, basophils, eosinophils and monocytes.

Disease Ontology: ¹¹ A myeloid leukemia that is characterized by the rapid growth of abnormal white blood cells that accumulate in the bone marrow and interfere with the production of normal blood cells.

Wikipedia: ⁷⁵ Acute myeloid leukemia (AML) is a cancer of the myeloid line of blood cells, characterized by the rapid... more...

More information from OMIM: 601626

Sources

Related Diseases for Leukemia, Acute Myeloid

Diseases in the Myeloid Leukemia family:

Leukemia, Acute Myeloid	Leukemia, Chronic Myeloid
Acute Myeloid Leukemia with T(6;9) (p23;q34.1)	Acute Myeloid Leukemia with T(8;21); (q22; Q22.1)
Acute Myeloid Leukemia with T(1;22)(p13;q13)	Subacute Myeloid Leukemia
Acute Myeloid Leukemia with T(9;11)(p22;q23)	Acute Myeloid Leukemia with T(9;22)(q34.1;q11.2)

Diseases related to Leukemia, Acute Myeloid via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1715)

#	Related Disease	Score	Top Affiliating Genes
1	acute megakaryocytic leukemia	33.8	TP53 RUNX1 KIT JAK2 GATA2 FLT3
2	acute myeloid leukemia with bcr-abl1	33.7	NPM1 IDH2 FLT3 DNMT3A
3	acute myelomonocytic leukemia	33.7	RUNX1 KIT FLT3 ETV6
4	core binding factor acute myeloid leukemia	33.5	NPM1 KIT FLT3 CEBPA
5	acute erythroid leukemia	33.5	TP53 KIT JAK2 GATA2 FLT3 CEBPA
6	acute basophilic leukemia	33.3	NUP214 KIT ETV6
7	childhood leukemia	33.1	NSD1 NPM1 MLLT10 KIT FLT3 ETV6
8	acute myeloblastic leukemia without maturation	33.1	NPM1 FLT3
9	platelet disorder, familial, with associated myeloid malignancy	33.1	RUNX1 ETV6
10	myeloid leukemia	33.1	TERT RUNX1 PICALM NUP214 NSD1 NPM1
11	myeloid and lymphoid neoplasms associated with pdgfra rearrangement	33.1	KIT JAK2 ETV6 CHIC2
12	diamond-blackfan anemia	33.0	TP53 TERT NPM1 KIT JAK2 GATA2
13	leukemia	32.9	TP53 RUNX1 PICALM NUP214 NPM1 MLLT10
14	acute biphenotypic leukemia	32.8	NUP214 MLLT10 KIT FLT3 ETV6
15	chronic myelomonocytic leukemia	32.7	TP53 RUNX1 NPM1 KRAS KIT JAK2
16	acute myeloid leukemia with t(8;21)(q22;q22) translocation	32.7	RUNX1 KIT FLT3 CEBPA
17	childhood acute myeloid leukemia	32.7	NUP214 NSD1 NPM1 MLLT10 KIT FLT3
18	dyskeratosis congenita	32.6	TP53 TERT NPM1 GATA2 CEBPA
19	shwachman-diamond syndrome 1	32.6	TP53 TERT GATA2 CEBPA
20	myelofibrosis	32.3	TP53 RUNX1 NPM1 KIT JAK2 IDH2
21	myelodysplastic syndrome	32.2	TP53 TERT RUNX1 NUP214 NSD1 NPM1
22	down syndrome	32.2	TP53 RUNX1 JAK2 FLT3 ETV6
23	leukemia, acute lymphoblastic	32.2	TP53 RUNX1 PICALM MLLT10 KRAS KIT
24	neutropenia	32.2	TP53 KRAS JAK2 FLT3 CEBPA
25	wilms tumor 1	32.1	TP53 TERT NPM1 KRAS KIT FLT3
26	thrombocytopenia	32.1	TERT RUNX1 KIT JAK2 GATA2 FLT3
27	nervous system disease	32.1	TP53 TERT KRAS KIT JAK2 IDH2
28	acute promyelocytic leukemia	31.9	TP53 TERT RUNX1 NPM1 KRAS KIT
29	juvenile myelomonocytic leukemia	31.9	RUNX1 NPM1 KRAS KIT JAK2 GATA2
30	pancytopenia	31.9	TP53 TERT RUNX1 KIT FLT3
31	hematologic cancer	31.9	RUNX1 PICALM NPM1 MLLT10 KIT JAK2
32	leukemia, chronic myeloid	31.8	TP53 RUNX1 NPM1 KRAS KIT JAK2
33	blood platelet disease	31.8	TP53 RUNX1 KIT JAK2 FLT3
34	bone marrow cancer	31.8	TP53 NPM1 KIT JAK2 FLT3 DNMT3A
35	leukemia, chronic lymphocytic	31.8	TP53 NPM1 KRAS KIT JAK2 FLT3
36	myeloid sarcoma	31.8	NPM1 KIT FLT3
37	acute leukemia	31.7	RUNX1 MLLT10 KRAS KIT JAK2 GATA2
38	atypical chronic myeloid leukemia, bcr-abl1 negative	31.7	JAK2 FLT3 ETV6
39	myeloma, multiple	31.7	TP53 KRAS JAK2 IDH2 FLT3 DNMT3A
40	essential thrombocythemia	31.6	TP53 TERT KIT JAK2 IDH2 FLT3
41	myeloproliferative neoplasm	31.6	RUNX1 KIT JAK2 FLT3 ETV6 DNMT3A
42	chronic leukemia	31.5	NPM1 KIT JAK2 IDH2 FLT3 ETV6
43	aggressive systemic mastocytosis	31.5	RUNX1 KIT JAK2 FLT3
44	sm-ahnmd	31.5	KIT JAK2 CHIC2
45	plasma cell neoplasm	31.4	TP53 KRAS IDH2 FLT3 DNMT3A
46	lymphoma, non-hodgkin, familial	31.4	TP53 NPM1 JAK2 FLT3 ETV6
47	polycythemia vera	31.4	TP53 KIT JAK2 IDH2 ETV6 DNMT3A
48	childhood acute lymphocytic leukemia	31.4	RUNX1 FLT3 ETV6
49	severe congenital neutropenia	31.3	RUNX1 JAK2 GATA2 CEBPA
50	precursor t-cell acute lymphoblastic leukemia	31.3	PICALM NUP214 MLLT10 FLT3 ETV6

Graphical network of the top 20 diseases related to Leukemia, Acute Myeloid:

Sources

Symptoms & Phenotypes for Leukemia, Acute Myeloid

Human phenotypes related to Leukemia, Acute Myeloid:

³⁰

#	Description	HPO Frequency	Orphanet Frequency	HPO Source Accession
1	acute myeloid leukemia ³⁰			HP:0004808

Symptoms via clinical synopsis from OMIM®:

⁵⁷ (Updated 08-Dec-2022)

Hematology:
acute myelogenous leukemia (aml)

Clinical features from OMIM®:

601626 (Updated 08-Dec-2022)

UMLS symptoms related to Leukemia, Acute Myeloid:

angina pectoris; chest pain; edema

GenomeRNAi Phenotypes related to Leukemia, Acute Myeloid according to GeneCards Suite gene sharing:

²⁵

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	no effect	GR00402-S-1	10.19	CEBPA CHIC2 DNMT3A ETV6 FLT3 GATA2
2	no effect	GR00402-S-2	10.19	CEBPA CHIC2 ETV6 FLT3 GATA2 IDH2
3	Reduced mammosphere formation	GR00396-S	9.5	CEBPA DNMT3A ETV6 IDH2 KRAS NUP214

MGI Mouse Phenotypes related to Leukemia, Acute Myeloid:

⁴⁵ (show all 16)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.41	CEBPA CHIC2 DNMT3A ETV6 FLT3 GATA2
2	growth/size/body region	MP:0005378	10.4	CEBPA CHIC2 DNMT3A ETV6 FLT3 GATA2
3	cellular	MP:0005384	10.36	CEBPA DNMT3A ETV6 FLT3 GATA2 IDH2
4	neoplasm	MP:0002006	10.3	CEBPA ETV6 FLT3 IDH2 JAK2 KIT
5	endocrine/exocrine gland	MP:0005379	10.29	CEBPA CHIC2 DNMT3A ETV6 FLT3 GATA2
6	embryo	MP:0005380	10.27	DNMT3A ETV6 GATA2 JAK2 KIT KRAS
7	liver/biliary system	MP:0005370	10.26	CEBPA ETV6 JAK2 KIT KRAS MLLT10
8	immune system	MP:0005387	10.24	CEBPA CHIC2 ETV6 FLT3 IDH2 JAK2
9	normal	MP:0002873	10.2	CEBPA ETV6 GATA2 JAK2 KIT KRAS
10	cardiovascular system	MP:0005385	10.18	CEBPA CHIC2 ETV6 GATA2 IDH2 JAK2
11	no phenotypic analysis	MP:0003012	10.14	CEBPA ETV6 FLT3 KIT KRAS NSD1
12	reproductive system	MP:0005389	10.06	CEBPA CHIC2 DNMT3A GATA2 JAK2 KIT
13	hematopoietic system	MP:0005397	10.06	CEBPA CHIC2 DNMT3A ETV6 FLT3 GATA2
14	skeleton	MP:0005390	10.03	CHIC2 DNMT3A ETV6 FLT3 IDH2 JAK2
15	mortality/aging	MP:0010768	9.91	CEBPA CHIC2 DNMT3A ETV6 FLT3 GATA2
16	integument	MP:0010771	9.36	CEBPA CHIC2 ETV6 JAK2 KIT KRAS

Sources

Drugs & Therapeutics for Leukemia, Acute Myeloid

Drugs for Leukemia, Acute Myeloid (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 558)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Nicotine

Approved

Phase 4

54-11-5

942 89594

Cytarabine

Approved, Investigational

Phase 4

147-94-4

6253

Idarubicin

Approved

Phase 4

58957-92-9

42890

Sargramostim

Approved, Investigational

Phase 4

123774-72-1

Histamine

Approved, Investigational

Phase 4

51-45-6

774

Posaconazole

Approved, Investigational, Vet_approved

Phase 4

171228-49-2

147912

Amsacrine

Approved, Investigational

Phase 4

51264-14-3

2179

Micafungin

Approved, Investigational

Phase 4

235114-32-6

477468

Lactitol

Approved, Investigational

Phase 4

585-86-4

157355

Lenalidomide

Approved

Phase 4

191732-72-6

216326

Cholecalciferol

Approved, Nutraceutical, Vet_approved

Phase 4

67-97-0, 1406-16-2

5280795 10883523

Ergocalciferol

Approved, Nutraceutical

Phase 4

50-14-6

5280793

Calcifediol

Approved, Nutraceutical

Phase 4

19356-17-3

5283731

Molgramostim

Investigational

Phase 4

99283-10-0

Cytochrome P-450 Enzyme Inhibitors

Phase 4

Anti-Bacterial Agents

Phase 4

Antibiotics, Antitubercular

Phase 4

Vitamin D2

Phase 4

3249

Calciferol

Phase 4

Ergocalciferols

Phase 4

Histamine phosphate

Phase 4

51-74-1

134614

Antiprotozoal Agents

Phase 4

Antiparasitic Agents

Phase 4

Hydroxycholecalciferols

Phase 4

homoharringtonine

Phase 4

3628

Heptavalent Pneumococcal Conjugate Vaccine

Phase 4

Angiogenesis Inhibitors

Phase 4

Dopamine

Approved

Phase 3

62-31-7, 51-61-6

681

Metoclopramide

Approved, Investigational

Phase 3

364-62-5

4168

Abatacept

Approved

Phase 3

332348-12-6

Miconazole

Approved, Investigational, Vet_approved

Phase 3

22916-47-8

4189

Clotrimazole

Approved, Vet_approved

Phase 3

23593-75-1

2812

Benzocaine

Approved, Investigational

Phase 3

1994-09-7, 94-09-7

2337

Tannic acid

Approved

Phase 3

1401-55-4

16129878 16129778

Sirolimus

Approved, Investigational

Phase 3

53123-88-9

5284616 6436030

Adenosine

Approved, Investigational

Phase 3

58-61-7

60961

Levofloxacin

Approved, Investigational

Phase 3

100986-85-4

149096

Ofloxacin

Approved

Phase 3

82419-36-1

4583

Lomustine

Approved, Investigational

Phase 3

13010-47-4

3950

Pentostatin

Approved, Investigational

Phase 3

53910-25-1

439693

Captopril

Approved

Phase 3

62571-86-2

44093

Morphine

Approved, Investigational

Phase 3

57-27-2

5288826

Cobalt

Approved, Experimental, Withdrawn

Phase 3

7440-48-4

104729

Carvedilol

Approved, Investigational

Phase 3

72956-09-3

2585

Nalbuphine

Approved

Phase 3

20594-83-6

5311304

Enalaprilat

Approved

Phase 3

76420-72-9

6917719 5462501

Enalapril

Approved, Vet_approved

Phase 3

75847-73-3

40466924 5388962 5362032

Chlorhexidine

Approved, Vet_approved, Withdrawn

Phase 3

55-56-1

2713 9552079

Mitoxantrone

Approved, Investigational

Phase 3

70476-82-3, 65271-80-9

4212

Mechlorethamine

Approved, Investigational

Phase 3

51-75-2

4033

Interventional clinical trials:

(show top 50) (show all 2619)

#	Name	Status	NCT ID	Phase	Drugs
1	A Randomized Comparison of Fludarabine in Combination With Cytarabine Versus High -Dose Cytarabine in Post-remission Therapy for AML1-ETO Acute Myeloid Leukemia	Unknown status	NCT02024308	Phase 4	Fludarabine;Cytarabine
2	Early Tapering of Immunosuppressive Agents After Allogeneic Hematopoietic Stem Cell Transplantation Can Improve the Survival of Patients With Advanced Acute Myeloid Leukemia.	Unknown status	NCT03150134	Phase 4	Cyclosporine;routine reduction of immunosuppressive drugs(cyclosporine)
3	Multicenter Randomised Clinical Trial in Acute Myeloid Leukemia Treatment Based on Three Anthracyclines, Comparing Two Types of Consolidation With Different ARA-C Doses Followed by One Year Maintenance	Unknown status	NCT01587430	Phase 4	high dose ARA-C;standard dose ARA-C
4	Decitabine for Myelodysplastic Syndromes and Acute Myeloid Leukemia Before Allogeneic Hematopoietic Cell Transplantation	Unknown status	NCT01806116	Phase 4	decitabine
5	Interferon for the Intervention of Molecular Relapse in t (8; 21) AML After Allo-HSCT	Unknown status	NCT02027064	Phase 4	Interferon-alpha
6	A Phase IV, Randomized Study to Evaluate the Safety and Efficacy of Idarubicin at Different Dosages Combined With Cytarabine as Induction Therapy for Newly Diagnosed Acute Myeloid Leukaemia	Unknown status	NCT02277847	Phase 4	Idarubicin(8mg/m2) and cytosine arabinoside;Idarubicin(10mg/m2), cytosine arabinoside
7	Treatment of Elderly Patients (>60 Years) With Acute Myeloblastic Leukemia or Advanced MDS (RAEB-T): An Open Randomized Study to Test the Efficacy of G-CSF-Priming and a Feasibility Trial of Dose-Reduced Allogeneic Transplantation and of Autologous Stem Cell Transplantation	Unknown status	NCT00199147	Phase 4	Cytarabine;Etoposide;Idarubicin;G-CSF;Fludarabine
8	G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor: a Prospective, Multicentre, Randomised Controlled Trial	Unknown status	NCT02933333	Phase 4
9	FLAT: Fludarabine, Cytarabine and Topotecan in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia	Completed	NCT00488709	Phase 4	Topotecan;Fludarabine;Cytarabine
10	A Clinical Trial to Evaluate the Efficacy and Safety of Recombinant Human Thrombopoietin in the Treatment of Thrombocytopenia After Chemotherapy in Acute Myeloid Leukemia	Completed	NCT02267993	Phase 4	recombinant human thrombopoietin
11	A SINGLE ARM, OPEN-LABEL, PHASE 4 STUDY EVALUATING QT INTERVAL, PHARMACOKINETICS, AND SAFETY OF GEMTUZUMAB OZOGAMICIN (MYLOTARG (TRADEMARKER)) AS A SINGLE-AGENT REGIMEN IN PATIENTS WITH RELAPSED OR REFRACTORY CD33-POSITIVE ACUTE MYELOID LEUKEMIA	Completed	NCT03727750	Phase 4	Gemtuzumab Ozogamicin
12	AML96 - Risk-Adapted and Randomized Postremission-Therapy for Adult Acute Myeloid Leukemia Patients. A Cooperative AML-Study of the German SHG-Study Group.	Completed	NCT00180115	Phase 4	Cytarabine Dosage
13	AML2003 - Randomized Comparison Between Standard-Therapy and Intensified Therapy for Adult Acute Myeloid Leukemia Patients <= 60 Years. A Prospective, Randomized, Multi-center Therapy-Optimizing-Study.	Completed	NCT00180102	Phase 4	Cytarabine vs. Cytarabine+Amsacrine+Mitoxantrone
14	PETHEMA LAM07: Prospective, Multicenter, Uncontrolled Cohort Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML)	Completed	NCT01041040	Phase 4	gemtuzumab
15	A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 (Stoss Therapy) in Pediatric Patients Undergoing HSCT to Prevent Vitamin D Deficiency and Insufficiency During Transplant	Completed	NCT03176849	Phase 4
16	Open-Label, Multicenter, Effects of Remission Maintenance Therapy With Ceplene® , Given in Conjunction With Low-Dose Interleukin-2, on Immune Response and Minimal Residual Disease in Adult Patients With AML in First Complete Remission	Completed	NCT01347996	Phase 4	histamine dihydrochloride and IL-2
17	Incidence of Respiratory Viral Infections During AML Induction and Consolidation Chemotherapy	Completed	NCT01819792	Phase 4
18	A Phase IV Study of Corticosteroids As Prophylaxis for Infusion-Related Adverse Events to Mylotarg® in Patients With Acute Myelogenous Leukemia (AML)	Completed	NCT00304447	Phase 4	Mylotarg
19	A Randomized Open-Label Trial of Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome	Completed	NCT01200355	Phase 4	micafungin;posaconazole
20	A Phase 4 Study of the Pharmacokinetics of Oral Posaconazole (SCH 56592) Among Patients With Compromised Gastrointestinal Function and at High Risk for Invasive Fungal Infection	Completed	NCT00686543	Phase 4	Posaconazole
21	FLAG-IDA Chemotherapy Induction Follow by Intensive Chemotherapy Postremission +/- Autologous Hemopoietic Stem Cell Transplantation or Bone Marrow Transplantation in Patients With High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia.	Completed	NCT00487448	Phase 4	Fludarabine;Cytarabine;G-CSF;Idarubicin
22	PETHEMA-LAM99:Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 Years	Completed	NCT00464217	Phase 4	ARA-C;Idarubicin;Leucomax
23	Fludarabine and Cytarabine Versus High-dose Cytarabine in Consolidation Treatment of Core-bing Factor Acute Myeloid Leukemia: A Prospective, Multicenter, Randomized Study	Recruiting	NCT02926586	Phase 4	Fludarabine;Cytarabine
24	Evaluation of Antibody Response to High-Dose Seasonal Influenza Vaccination in Patients With Myeloid Malignancy Receiving Chemotherapy	Recruiting	NCT04484532	Phase 4
25	Immunogénicité de la Vaccination Anti-pneumococcique Dans la leucémie aiguë et le Lymphome Chez l'Adulte	Recruiting	NCT04460235	Phase 4	Prevenar13 Pneumo-23
26	Open Label, Multi-center, Phase IV Study of Ruxolitinib or Ruxolitinib and Panobinostat Combination, for Patients Who Have Completed Prior Global Novartis or Incyte Sponsored Studies	Recruiting	NCT02386800	Phase 4	ruxolitinib;panobinostat
27	The Efficacy and Safety of Azacytidine Combined With HAG Regimen Versus Azacytidine for Elderly Patients With Newly Diagnosed Myeloid Malignancy: a Prospective, Randomized Controlled Trial	Recruiting	NCT03873311	Phase 4	Azacytidine, HAG Regimen;Azacytidine
28	A Prospective, Randomized, Controlled Trial of Decitabine Versus Conventional Chemotherapy for Maintenance Therapy of Patients With Acute Myeloid Leukemia With t(8;21)	Active, not recruiting	NCT03026842	Phase 4	Decitabine;Daunorubicin, Cytarabine;Mitoxantrone, Cytarabine;Aclacinomycin, Cytarabine
29	A Phase 4 Study of Venetoclax in Combination With Azacitidine in Newly Diagnosed Subjects With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy in China	Active, not recruiting	NCT05144243	Phase 4	Venetoclax;Azacitidine
30	The Feasibility of Safely Managing Patients Receiving Induction With Liposomal Daunorubicin and Cytarabine (CPX-351) for Acute Myeloid Leukemia (AML) in an Outpatient Environment	Terminated	NCT03988205	Phase 4	CPX-351
31	PILOT STUDY PHASE II, Multicenter, Non-randomized, TO ASSESS THE EFFICACY AND SAFETY OF LENALIDOMIDE IN INDUCTION AND POST-INDUCTION IN PATIENTS WITH NOVO Acute Myeloid Leukemia (AML) WITH Cytogenetic Abnormality Monosomy 5	Terminated	NCT01198054	Phase 4	Lenalidomide
32	Randomized, Open-Label Study of the Efficacy and Safety of Galinpepimut-S Maintenance Therapy Compared to Best Available Therapy in Acute Myeloid Leukemia Patients Who Have Achieved Complete Remission After Second-Line Salvage Therapy	Unknown status	NCT04229979	Phase 3	Best Available Therapy
33	Eltrombopag Used in Thrombocytopenia After Comsolidation Therapy in Acute Myeloid Leukemia (AML)	Unknown status	NCT03701217	Phase 2, Phase 3	Eltrombopag
34	Phase III Open-Label Randomized Study of Amonafide L-Malate in Combination With Cytarabine Compared to Daunorubicin in Combination With Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- The ACCEDE Study	Unknown status	NCT00715637	Phase 3	Daunorubicin and Cytarabine;Amonafide and Cytarabine
35	Haplo-mismatch Donor Stem Cell Transplantation (SCT) Versus Autologous SCT Followed or Not by Maintenance Therapy, for Patients With Acute Myeloid Leukemia (AML) in First Remission: A Chinese Randomized Multicenter Study	Unknown status	NCT02059720	Phase 3
36	Efficacy and Safety of Decitabine in Combination With Low-dose Cytarabine as Inductive Treatment in Newly Diagnosed Elderly Patients With Acute Myeloid Leukemia	Unknown status	NCT02985372	Phase 3	Decitabine;Cytarabine
37	A Phase 3, Randomized, Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Decitabine Combined With HAAG Regimen in Newly Diagnosed Acute Myeloid Leukemia Patients Younger Than 60 Years	Unknown status	NCT04087967	Phase 3	Decitabine plus HAAG regimen;Idarubicine plus Cytarabine regimen
38	A Phase 3, Open Label, Single Arm, Multi-Center Study to Evaluate the Efficacy and Safety of Decitabine Combined With HAAG Regimen in Elderly Newly Diagnosed Acute Myeloid Leukemia Patients.	Unknown status	NCT04083911	Phase 3	Decitabine, Homoharringtonine, Aclarubicin, Cytarabine and G-CSF
39	The Effect of Granulocyte-colony Stimulating Factor (G-CSF) on Minimal Residual Disease (MRD) After Induction Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML)	Unknown status	NCT03665480	Phase 2, Phase 3	G-SCF
40	A Prospective Randomized Comparison of Idarubicin and High-dose Daunorubicin in Combination With Cytarabine in the Induction Chemotherapy for Acute Myeloid Leukemia	Unknown status	NCT01145846	Phase 3	Cytarabine plus Daunorubicin [Arm II (AD regimen)]
41	Multicenter Protocol in Treating Patients With Childhood Acute Myeloid Leukemia. Randomized Study of Maintenance Treatment With Interleukin-2	Unknown status	NCT00149162	Phase 3	proleukin
42	CD123/CLL1 CAR-T Cell Therapy for Relapsed and Refractory Acute Myeloid Leukemia	Unknown status	NCT03631576	Phase 2, Phase 3
43	Low Dose Decitabine + Modified BUCY Conditioning Regimen for High Risk Acute Myeloid Leukemia Undergoing Allo-HSCT	Unknown status	NCT03256071	Phase 2, Phase 3	Decitabine plus Modified BUCY;Modified BUCY
44	Decitabine+ Fludarabine+Busulfan Conditioning Regimen for Elderly Acute Myeloid Leukemia in Complete Remission Undergoing Allogeneic Hematopoietic Stem Cell Transplantation	Unknown status	NCT03530085	Phase 2, Phase 3	Decitabine;Busulfan (BU);Fludarabine(Flu)
45	Phase III Clinical Trial of Microtransplantation to Treat Elderly Acute Myeloid Leukemia	Unknown status	NCT02171117	Phase 3
46	A Prospective Randomized Comparison of High-dose Cytarabine an High-dose Daunorubicin in the Induction Chemothrapy for Acute Myeloid Leukemia	Unknown status	NCT03507842	Phase 3	High dose Cytarabine;Cytarabine;Hign dose Daunorubicin
47	A Multi-center, Open, Randomized-control Study to Compare the Effects and Safety of Idarubicin-strengthened Pretreatment Program and Conventional Busulfan Cyclophosphamide Pretreatment Program on High-risk Acute Myeloid Leukemia Patient	Unknown status	NCT01766375	Phase 3	Cyclosporin A,mycophenolate mofetil,Methotrexate
48	HLA-mismatched Microtransplantation for High Risk Acute Myeloid Leukemia	Unknown status	NCT01484171	Phase 3	idarubicin
49	Decitabine Augments for Post Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome	Unknown status	NCT01809392	Phase 2, Phase 3	decitabine
50	The Comparison of Transplantation From Family-mismatched/Haploidentical Donors With Matched Unrelated Donors in Adult Patients With Acute Myeloid Leukemia	Unknown status	NCT01751997	Phase 2, Phase 3	Transplants from 8/8-matched Unrelated donors;Transplants from family-mismatched/haploidentical donors

Search NIH Clinical Center for Leukemia, Acute Myeloid

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵⁰ :

Cyclophosphamide

Etoposide

etoposide phosphate

Idarubicin

Idarubicin Hydrochloride

Mitoxantrone

Mitoxantrone Hydrochloride

Cell-based therapeutics:

Data from LifeMap, the Embryonic Development and Stem Cells Database

Read about Leukemia, Acute Myeloid cell therapies at LifeMap Discovery.

Stem-cell-based therapeutic approaches for Leukemia, Acute Myeloid:

	Hemacord, umbilical cord blood-derived hematopoietic progenitor cells for hematopoietic reconstitution
	Hematopoietic stem cells for treatment of hematologic malignancies
	NiCord, umbilical cord blood-derived stem/progenitor cells for hemotological diseases
	Peripheral blood stem cells for treatment of hematologic malignancies
	StemEx, umbilical cord blood stem/progenitor cells for hematological diseases

Embryonic/Adult Cultured Cells Related to Leukemia, Acute Myeloid:

	Umbilical cord blood-derived hematopoietic progenitor cells (HEMACORD) PMIDs: 9828244
	Bone marrow-derived hematopoietic stem cells
	Umbilical cord blood-derived stem cells (NiCord) PMIDs: 22198152
	Peripheral blood-derived hematopoietic stem cells (family)
	Umbilical cord blood stem/progenitor cells (Stemex) PMIDs: 18209724

Sources

Genetic Tests for Leukemia, Acute Myeloid

Genetic tests related to Leukemia, Acute Myeloid:

#	Genetic test	Affiliating Genes
1	Acute Myeloid Leukemia ²⁸	CEBPA CHIC2 DNMT3A ETV6 FLT3 GATA2 JAK2 KIT KRAS LPP MLLT10 NPM1 NUP214 PICALM RUNX1 SH3GL1 TERT
2	Leukemia, Acute Myeloid, Susceptibility to ²⁸
3	Therapy Related Acute Myeloid Leukemia and Myelodysplastic Syndrome ²⁸

Sources

Anatomical Context for Leukemia, Acute Myeloid

Organs/tissues related to Leukemia, Acute Myeloid:

MalaCards : Myeloid, Bone Marrow, Bone, T Cells, Nk Cells, Monocytes, Skin

ODiseA: Blood And Bone Marrow

Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Leukemia, Acute Myeloid:

#	Tissue Anatomical CompartmentCell	Relevance
1	Blood Hematopoietic Bone Marrow Common Myeloid Progenitor Cells	Affected by disease
2	Blood Hematopoietic Bone Marrow Hematopoietic Stem Cells	Potential therapeutic candidate

Sources

Publications for Leukemia, Acute Myeloid

Articles related to Leukemia, Acute Myeloid:

(show top 50) (show all 46135)

#	Title	Authors	PMID	Year
1	Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. ⁵³ ⁶² ⁵⁷ ⁵	Falini B...GIMEMA Acute Leukemia Working Party	15659725	2005
2	Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. ⁶² ⁵⁷ ⁵	Cancer Genome Atlas Research Network...Eley G	23634996	2013
3	Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. ⁶² ⁵⁷ ⁵	Smith CC...Shah NP	22504184	2012
4	Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia. ⁶² ⁵⁷ ⁵	Hahn CN...Scott HS	21892162	2011
5	Recurring mutations found by sequencing an acute myeloid leukemia genome. ⁶² ⁵⁷ ⁵	Mardis ER...Ley TJ	19657110	2009
6	Constitutional hypomorphic telomerase mutations in patients with acute myeloid leukemia. ⁶² ⁵⁷ ⁵	Calado RT...Young NS	19147845	2009
7	Somatic heterozygous mutations in ETV6 (TEL) and frequent absence of ETV6 protein in acute myeloid leukemia. ⁶² ⁵⁷ ⁵	Barjesteh van Waalwijk van Doorn-Khosrovani S...Delwel R	15806161	2005
8	Mutation of CEBPA in familial acute myeloid leukemia. ⁶² ⁵⁷ ⁵	Smith ML...Fitzgibbon J	15575056	2004
9	Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. ⁶² ⁴⁶ ⁵⁷	Garzon R...Falini B	18308931	2008
10	The JAK2 V617F mutation in de novo acute myelogenous leukemias. ⁵⁷ ⁵	Lee JW...Lee SH	16247455	2006
11	Biochemical characterization of a novel KRAS insertion mutation from a human leukemia. ⁵⁷ ⁵	Bollag G...Shannon K	8955068	1996
12	High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder. ⁵³ ⁶² ⁵	Preudhomme C...Sobol H	19357396	2009
13	The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants. ⁶² ⁵	Rio-Machin A...Dokal I	32098966	2020
14	Gain-of-Function Effects of N-Terminal CEBPA Mutations in Acute Myeloid Leukemia. ⁶² ⁵	Schmidt L...Grebien F	31867767	2020
15	Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. ⁶² ⁵⁷	Perl AE...Levis MJ	31665578	2019
16	Coordinated alterations in RNA splicing and epigenetic regulation drive leukaemogenesis. ⁶² ⁵⁷	Yoshimi A...Abdel-Wahab O	31578525	2019
17	ClinGen Myeloid Malignancy Variant Curation Expert Panel recommendations for germline RUNX1 variants. ⁶² ⁵	Luo X...Godley LA	31648317	2019
18	Germline CEBPA mutations in Korean patients with acute myeloid leukemia. ⁶² ⁵	Kim HS...Cho B	30563700	2019
19	Ivosidenib in IDH1-Mutated Acute Myeloid Leukemia. ⁶² ⁵	DiNardo CD	30231226	2018
20	Prediction of acute myeloid leukaemia risk in healthy individuals. ⁶² ⁵⁷	Abelson S...Shlush LI	29988082	2018
21	BCAT1 restricts αKG levels in AML stem cells leading to IDHmut-like DNA hypermethylation. ⁶² ⁵⁷	Raffel S...Trumpp A	29144447	2017
22	The spectrum of DNMT3A variants in Tatton-Brown-Rahman syndrome overlaps with that in hematologic malignancies. ⁶² ⁵	Shen W...Carey JC	28941052	2017
23	Acute myeloid leukemia-associated DNMT3A p.Arg882His mutation in a patient with Tatton-Brown-Rahman overgrowth syndrome as a constitutional mutation. ⁶² ⁵	Kosaki R...Kosaki K	27991732	2017
24	Germline heterozygous DDX41 variants in a subset of familial myelodysplasia and acute myeloid leukemia. ⁶² ⁵	Cardoso SR...Dokal I	27133828	2016
25	Two novel germline DDX41 mutations in a family with inherited myelodysplasia/acute myeloid leukemia. ⁶² ⁵	Li R...Braunstein EM	26944477	2016
26	Assessment of Minimal Residual Disease in Standard-Risk AML. ⁶² ⁵⁷	Ivey A...UK National Cancer Research Institute AML Working Group	26789727	2016
27	BET inhibitor resistance emerges from leukaemia stem cells. ⁶² ⁵⁷	Fong CY...Dawson MA	26367796	2015
28	Transcriptional plasticity promotes primary and acquired resistance to BET inhibition. ⁶² ⁵⁷	Rathert P...Zuber J	26367798	2015
29	Disease evolution and outcomes in familial AML with germline CEBPA mutations. ⁶² ⁵	Tawana K...Fitzgibbon J	26162409	2015
30	Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. ⁶² ⁵⁷	Wong TN...Wilson RK	25487151	2015
31	Chemical biology. A small-molecule inhibitor of the aberrant transcription factor CBFβ-SMMHC delays leukemia in mice. ⁶² ⁵⁷	Illendula A...Bushweller JH	25678665	2015
32	DNA-damage-induced differentiation of leukaemic cells as an anti-cancer barrier. ⁶² ⁵⁷	Santos MA...Nussenzweig A	25079327	2014
33	Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients. ⁶² ⁵	Kihara R...Naoe T	24487413	2014
34	Relapse assessment following allogeneic SCT in patients with MDS and AML. ⁶² ⁵	Christopeit M...Bacher U	24671364	2014
35	WT1 overexpression affecting clinical outcome in non-hodgkin lymphomas and adult acute lymphoblastic leukemia. ⁶² ⁵	Ujj Z...Rejto L	24374862	2014
36	Minimal residual disease monitoring in t(8;21) acute myeloid leukemia based on RUNX1-RUNX1T1 fusion quantification on genomic DNA. ⁶² ⁵	Duployez N...Renneville A	24616160	2014
37	Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies. ⁶² ⁵	Zhang W...Andreeff M	24619500	2014
38	The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers. ⁶² ⁵	Russler-Germain DA...Ley TJ	24656771	2014
39	WT1 vaccination in acute myeloid leukemia: new methods of implementing adoptive immunotherapy. ⁶² ⁵	Rein LA...Chao NJ	24521058	2014
40	Haploinsufficiency of del(5q) genes, Egr1 and Apc, cooperate with Tp53 loss to induce acute myeloid leukemia in mice. ⁶² ⁵	Stoddart A...Le Beau MM	24381225	2014
41	Wilms' Tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responses. ⁶² ⁵	Uttenthal B...Morris EC	24422723	2014
42	Clinical impact of gene mutations and lesions detected by SNP-array karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: results of the ALFA-0701 trial. ⁶² ⁵	Renneville A...Preudhomme C	24659740	2014
43	RUNX1 mutation associated with clonal evolution in relapsed pediatric acute myeloid leukemia with t(16;21)(p11;q22). ⁶² ⁵	Ismael O...Kojima S	24374719	2014
44	Leukaemogenesis induced by an activating β-catenin mutation in osteoblasts. ⁶² ⁵⁷	Kode A...Kousteni S	24429522	2014
45	Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. ⁶² ⁵⁷	Shlush LI...Dick JE	24522528	2014
46	Molecular evaluation of DNMT3A and IDH1/2 gene mutation: frequency, distribution pattern and associations with additional molecular markers in normal karyotype Indian acute myeloid leukemia patients. ⁶² ⁵	Ahmad F...Das BR	24606448	2014
47	Prognostic significance of TP53 mutations and single nucleotide polymorphisms in acute myeloid leukemia: a case series and literature review. ⁶² ⁵	Zeichner SB...Poppiti RJ	24641375	2014
48	Overexpression of Wilms tumor 1 gene as a negative prognostic indicator in acute myeloid leukemia. ⁶² ⁵	Lyu X...Zhao RY	24667279	2014
49	Proliferation and survival signaling from both Jak2-V617F and Lyn involving GSK3 and mTOR/p70S6K/4EBP1 in PVTL-1 cell line newly established from acute myeloid leukemia transformed from polycythemia vera. ⁶² ⁵	Nagao T...Miura O	24404189	2014
50	Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia. ⁶² ⁵	Zimmerman EI...Baker SD	24046014	2013

Sources

Genes for Leukemia, Acute Myeloid

Genes related to Leukemia, Acute Myeloid (34 elite genes):

(show top 50) (show all 518)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	CEBPA	CCAAT Enhancer Binding Protein Alpha	Protein Coding	1733.57	Molecular basis known ⁵⁷ Pathogenic/Likely pathogenic ⁵ Causative somatic mutation ⁵⁸ Causative variation ⁷³ Genetic Tests ²⁸ Unconfirmed association ⁵⁷ Likely pathogenic ⁵ DISEASES inferred ¹⁴	11242107 12661007 12692518 (more) 15575056 17671232 18752591 19171880 26162409 30563700 31867767 32430494 19357394 22649106
2	GATA2	GATA Binding Protein 2	Protein Coding	1432.8	Molecular basis known ⁵⁷ Pathogenic ⁵ Causative germline mutation ⁵⁸ Genetic Tests ²⁸ Susceptibility factor ⁵⁷ Likely pathogenic ⁵ DISEASES inferred ¹⁴	21892162 25397911 20040766 (more) 21242295 21670465 21765025 22147895
3	DNMT3A	DNA Methyltransferase 3 Alpha	Protein Coding	1333.6	Molecular basis known ⁵⁷ Pathogenic/Likely pathogenic ⁵ Causative variation ⁷³ Genetic Tests ²⁸ Likely pathogenic ⁵ DISEASES inferred ¹⁴	21067377 21518476 22160010 (more) 22744846 22898539 22898540 22898541 24606448 24656771 26619011 27991732 28941052 32581362
4	JAK2	Janus Kinase 2	Protein Coding	1307.98	Molecular basis known ⁵⁷ Pathogenic ⁵ Causative variation ⁷³ Genetic Tests ²⁸ DISEASES inferred ¹⁴	15793561 15858187 16247455 (more) 16325696 16603627 16707754 16762626 17989398 18256599 19036091 19293426 20339092 20631743 20703299 21120162 21689158 22041374 22422826 22571758 22818858 22829971 23115274 24404189 25043017 25671252
5	TERT	Telomerase Reverse Transcriptase	Protein Coding	1081.57	Molecular basis known ⁵⁷ Pathogenic ⁵ Genetic Tests ²⁸ Susceptibility factor ⁵⁷ Risk factor ⁵ DISEASES inferred ¹⁴	19147845
6	FLT3	Fms Related Receptor Tyrosine Kinase 3	Protein Coding	1042.12	Molecular basis known ⁵⁷ Pathogenic ⁵ Genetic Tests ²⁸ Likely pathogenic ⁵ DISEASES inferred ¹⁴ Novoseek inferred ⁵³	11091200 11290608 11442493 (more) 12384447 14604974 14670924 15256420 15374878 15863200 16857985 17047150 17387224 17606455 17889720 17942876 19602710 19657110 19840437 20733134 22368270 22504183 22504184 22504185 22504186 23261068 23321257 23430109 23714533 23783394 24046014 25157968 14737077 15625552 15667533 16091740 16371029 16410449 16573742 16990784 23878140 24619500 12551822
7	NPM1	Nucleophosmin 1	Protein Coding	1038.8	Molecular basis known ⁵⁷ Pathogenic ⁵ Genetic Tests ²⁸ Likely pathogenic ⁵ DISEASES inferred ¹⁴ Novoseek inferred ⁵³	15659725 32581362 19657110
8	RUNX1	RUNX Family Transcription Factor 1	Protein Coding	1038.49	Molecular basis known ⁵⁷ Pathogenic ⁵ Genetic Tests ²⁸ Likely pathogenic ⁵ DISEASES inferred ¹⁴ Novoseek inferred ⁵³	20722699 10508512 19357396 (more) 24374719 24616160 24659740 31648317 32098966 11264187 10825008
9	KIT	KIT Proto-Oncogene, Receptor Tyrosine Kinase	Protein Coding	1033.58	Molecular basis known ⁵⁷ Pathogenic ⁵ Genetic Tests ²⁸ Likely pathogenic ⁵ DISEASES inferred ¹⁴	7513208 8589724 9657776 (more) 16384925 18986703 19164557 19865100 22504184 23714533 24045550 23149070
	KIT::MIR221 ⁴⁶	MIR221 Macro RNA (hsa-miR-221) targets KIT
	KIT::MIR222 ⁴⁶	MIR222 Macro RNA (hsa-miR-222) targets KIT
10	KRAS	KRAS Proto-Oncogene, GTPase	Protein Coding	1032.17	Molecular basis known ⁵⁷ Pathogenic ⁵ Genetic Tests ²⁸ Likely pathogenic ⁵ DISEASES inferred ¹⁴	2278970 3122217 8955068 (more) 16434492 16474405 19075190 20949621 22407852 24803665 26619011
11	ETV6	ETS Variant Transcription Factor 6	Protein Coding	1013.49	Molecular basis known ⁵⁷ Pathogenic ⁵ Genetic Tests ²⁸ DISEASES inferred ¹⁴ Novoseek inferred ⁵³	15806161 12661008
12	TGM6	Transglutaminase 6	Protein Coding	753.22	Pathogenic ⁵ Causative germline mutation ⁵⁸ DISEASES inferred ¹⁴	24755948
13	CHIC2	Cysteine Rich Hydrophobic Domain 2	Protein Coding	655.02	Molecular basis known ⁵⁷ Genetic Tests ²⁸ Susceptibility factor ⁵⁷ DISEASES inferred ¹⁴
14	PICALM	Phosphatidylinositol Binding Clathrin Assembly Protein	Protein Coding	613.38	Molecular basis known ⁵⁷ Genetic Tests ²⁸ DISEASES inferred ¹⁴ GeneCards inferred via : Summaries (show sections)
15	MLLT10	MLLT10 Histone Lysine Methyltransferase DOT1L Cofactor	Protein Coding	607.36	Molecular basis known ⁵⁷ Genetic Tests ²⁸ DISEASES inferred ¹⁴
16	NUP214	Nucleoporin 214	Protein Coding	606.98	Molecular basis known ⁵⁷ Genetic Tests ²⁸ DISEASES inferred ¹⁴
17	LPP	LIM Domain Containing Preferred Translocation Partner In Lipoma	Protein Coding	603.58	Molecular basis known ⁵⁷ Genetic Tests ²⁸ DISEASES inferred ¹⁴
18	IDH2	Isocitrate Dehydrogenase (NADP(+)) 2	Protein Coding	433.53	Pathogenic ⁵ Likely pathogenic ⁵ DISEASES inferred ¹⁴	20946881 21250968 21596855 (more) 22160010 22397365 22417203 22616558 22898539 23558173 23815907 23949315 24606448 25157968 26619011
19	TP53	Tumor Protein P53	Protein Coding	433.52	Pathogenic ⁵ Likely pathogenic ⁵ DISEASES inferred ¹⁴	28492532 20013323 24381225 (more) 24487413 24641375 25157968 26619011
20	NSD1	Nuclear Receptor Binding SET Domain Protein 1	Protein Coding	431.56	Pathogenic ⁵ Likely pathogenic ⁵ DISEASES inferred ¹⁴	15942875
21	DDX41	DEAD-Box Helicase 41	Protein Coding	431.38	Pathogenic ⁵ Likely pathogenic ⁵ DISEASES inferred ¹⁴	26944477 27133828
22	IDH1	Isocitrate Dehydrogenase (NADP(+)) 1	Protein Coding	408.5	Pathogenic ⁵ DISEASES inferred ¹⁴	19657110 20946881 22160010 (more) 22397365 22417203 22898539 24606448 26619011 30231226
23	BCOR	BCL6 Corepressor	Protein Coding	404.76	Pathogenic ⁵ DISEASES inferred ¹⁴
24	DNAJC21	DnaJ Heat Shock Protein Family (Hsp40) Member C21	Protein Coding	404.75	Pathogenic ⁵ DISEASES inferred ¹⁴
25	RTEL1	Regulator Of Telomere Elongation Helicase 1	Protein Coding	404.69	Pathogenic ⁵ DISEASES inferred ¹⁴
26	INSL6	Insulin Like 6	Protein Coding	400	Pathogenic ⁵	15793561 15858187 16247455 (more) 16325696 16603627 16707754 16762626 17989398 18256599 19036091 19293426 20339092 20631743 20703299 21120162 21689158 22041374 22422826 22571758 22818858 22829971 23115274 24404189 25043017 25671252
27	RTEL1-TNFRSF6B	RTEL1-TNFRSF6B Readthrough (NMD Candidate)	RNA Gene	400	Pathogenic ⁵
28	MIR126	MicroRNA 126	RNA Gene	360.33	Causal ⁴⁶ DISEASES inferred ¹⁴ ¹⁴	18832181
29	MIR34B	MicroRNA 34b	RNA Gene	356.19	Causal ⁴⁶ DISEASES inferred ¹⁴ ¹⁴	19258499
30	MIR204	MicroRNA 204	RNA Gene	355.21	Causal ⁴⁶ DISEASES inferred ¹⁴	18308931
31	ERCC6L2	ERCC Excision Repair 6 Like 2	Protein Coding	354.4	Causative germline mutation ⁵⁸ DISEASES inferred ¹⁴	30936069
32	MIR320A	MicroRNA 320a	RNA Gene	354.15	Causal ⁴⁶ DISEASES inferred ¹⁴	19135902
33	SETBP1	SET Binding Protein 1	Protein Coding	306.81	Causative variation ⁷³ DISEASES inferred ¹⁴
34	SH3GL1	SH3 Domain Containing GRB2 Like 1, Endophilin A2	Protein Coding	155.42	Genetic Tests ²⁸ Genetic association ⁵⁷ DISEASES inferred ¹⁴
35	HOTAIR	HOX Transcript Antisense RNA	RNA Gene	155.76	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴	25979172 26261618 26622861 (more) 28669171
36	HOTAIRM1	HOXA Transcript Antisense RNA, Myeloid-Specific 1	RNA Gene	155.69	Experimental evidence: Locus ³⁷ DISEASES inferred ¹⁴	26436590
37	UCA1	Urothelial Cancer Associated 1	RNA Gene	155.14	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	26053097
38	IRAIN	IGF1R Antisense Imprinted Non-Protein Coding RNA	RNA Gene	155.09	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	25092925
39	CDKN2B-AS1	CDKN2B Antisense RNA 1	RNA Gene	155.06	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	18185590 21414664
40	CCAT1	Colon Cancer Associated Transcript 1	RNA Gene	155.02	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	26923190
41	CCDC26	CCDC26 Long Non-Coding RNA	RNA Gene	155.01	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	25928165
42	TUG1	Taurine Up-Regulated 1	Protein Coding	154.74	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴	29654398
43	WT1-AS	WT1 Antisense RNA	RNA Gene	154.71	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	10340388 17940140
44	MEG3	Maternally Expressed 3	RNA Gene	154.25	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	19595458
45	MALAT1	Metastasis Associated Lung Adenocarcinoma Transcript 1	RNA Gene	153.81	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴	28713913
46	TUSC7	Tumor Suppressor Candidate 7	RNA Gene	153.18	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴	26345353
47	MIR223HG	MIR223 Host Gene	RNA Gene	150	Experimental evidence ³⁷	27517498
48	MIR142	MicroRNA 142	RNA Gene	59.86	Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴	18478077
49	MIR155	MicroRNA 155	RNA Gene	59.77	Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴	18308931
50	MIR21	MicroRNA 21	RNA Gene	59.75	Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴	18056805

Sources

Variations for Leukemia, Acute Myeloid

ClinVar genetic disease variations for Leukemia, Acute Myeloid:

⁵ (show top 50) (show all 1021)

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	Position
1	JAK2, INSL6	NM_004972.4(JAK2):c.1821G>C (p.Lys607Asn)	SNV	Pathogenic	14663	rs121912472	GRCh37: 9:5073742-5073742 GRCh38: 9:5073742-5073742
2	FLT3	NM_004119.3(FLT3):c.2508C>G (p.Ile836Met)	SNV	Pathogenic	375969	rs121913232	GRCh37: 13:28592637-28592637 GRCh38: 13:28018500-28018500
3	FLT3	NM_004119.3(FLT3):c.2505T>A (p.Asp835Glu)	SNV	Pathogenic	375972	rs121913487	GRCh37: 13:28592640-28592640 GRCh38: 13:28018503-28018503
4	DNMT3A	NM_022552.5(DNMT3A):c.2644C>G (p.Arg882Gly)	SNV	Pathogenic	375883	rs377577594	GRCh37: 2:25457243-25457243 GRCh38: 2:25234374-25234374
5	KIT	NM_000222.3(KIT):c.2446_2447delinsAT (p.Asp816Ile)	INDEL	Pathogenic	375926	rs1057519709	GRCh37: 4:55599320-55599321 GRCh38: 4:54733154-54733155
6	FLT3	NM_004119.3(FLT3):c.2506A>C (p.Ile836Leu)	SNV	Pathogenic	375970	rs1057519726	GRCh37: 13:28592639-28592639 GRCh38: 13:28018502-28018502
7	FLT3	NM_004119.3(FLT3):c.2503G>T (p.Asp835Tyr)	SNV	Pathogenic	16276	rs121913488	GRCh37: 13:28592642-28592642 GRCh38: 13:28018505-28018505
8	FLT3	NM_004119.3(FLT3):c.2503G>A (p.Asp835Asn)	SNV	Pathogenic	16274	rs121913488	GRCh37: 13:28592642-28592642 GRCh38: 13:28018505-28018505
9	FLT3	NM_004119.3(FLT3):c.2503G>C (p.Asp835His)	SNV	Pathogenic	16273	rs121913488	GRCh37: 13:28592642-28592642 GRCh38: 13:28018505-28018505
10	FLT3	NM_004119.3(FLT3):c.2504A>T (p.Asp835Val)	SNV	Pathogenic	16272	rs121909646	GRCh37: 13:28592641-28592641 GRCh38: 13:28018504-28018504
11	FLT3	FLT3, INTERNAL TANDEM DUP	DUP	Pathogenic	16270		GRCh37: GRCh38:
12	NPM1	NM_002520.7(NPM1):c.863_864insCCTG (p.Trp288fs)	INSERT	Pathogenic	14001	rs1554138189	GRCh37: 5:170837544-170837545 GRCh38: 5:171410540-171410541
13	NPM1	NM_002520.7(NPM1):c.863_864insCGTG (p.Trp288fs)	INSERT	Pathogenic	14000	rs1554138188	GRCh37: 5:170837545-170837546 GRCh38: 5:171410541-171410542
14	NPM1	NM_002520.7(NPM1):c.863_864insCATG (p.Trp288fs)	INSERT	Pathogenic	13999	rs1554138188	GRCh37: 5:170837545-170837546 GRCh38: 5:171410541-171410542
15	NPM1	NM_002520.7(NPM1):c.860_863dup (p.Trp288fs)	DUP	Pathogenic	13998	rs587776806	GRCh37: 5:170837543-170837544 GRCh38: 5:171410539-171410540
16	ETV6	NM_001987.5(ETV6):c.1307_1308insGGG (p.His436delinsGlnGly)	INSERT	Pathogenic	8985	rs587776710	GRCh37: 12:12043928-12043929 GRCh38: 12:11890994-11890995
17	ETV6	NM_001987.5(ETV6):c.226G>T (p.Glu76Ter)	SNV	Pathogenic	8984	rs121434637	GRCh37: 12:11992136-11992136 GRCh38: 12:11839202-11839202
18	DNMT3A	NM_022552.5(DNMT3A):c.2644C>A (p.Arg882Ser)	SNV	Pathogenic	375884	rs377577594	GRCh37: 2:25457243-25457243 GRCh38: 2:25234374-25234374
19	FLT3	NM_004119.3(FLT3):c.2504A>C (p.Asp835Ala)	SNV	Pathogenic	375973	rs121909646	GRCh37: 13:28592641-28592641 GRCh38: 13:28018504-28018504
20	FLT3	NM_004119.3(FLT3):c.2505T>G (p.Asp835Glu)	SNV	Pathogenic	375971	rs121913487	GRCh37: 13:28592640-28592640 GRCh38: 13:28018503-28018503
21	IDH1	NM_005896.4(IDH1):c.395G>C (p.Arg132Pro)	SNV	Pathogenic	375890	rs121913500	GRCh37: 2:209113112-209113112 GRCh38: 2:208248388-208248388
22	DNMT3A	NM_022552.5(DNMT3A):c.2645G>T (p.Arg882Leu)	SNV	Pathogenic	375879	rs147001633	GRCh37: 2:25457242-25457242 GRCh38: 2:25234373-25234373
23	NPM1	NM_002520.7(NPM1):c.869_875delinsCCCTGGCTAGG (p.Trp290fs)	INDEL	Pathogenic	632551	rs1561878500	GRCh37: 5:170837553-170837559 GRCh38: 5:171410549-171410555
24	DDX41	NM_016222.4(DDX41):c.719delinsCG (p.Ile240fs)	INDEL	Pathogenic	978203	rs1761157695	GRCh37: 5:176941996-176941996 GRCh38: 5:177514995-177514995
25	CEBPA	NM_004364.5(CEBPA):c.320del (p.Asp107fs)	DEL	Pathogenic	653792	rs1600023511	GRCh37: 19:33793001-33793001 GRCh38: 19:33302095-33302095
26	BCOR	NM_001123385.2(BCOR):c.4751del (p.Asn1584fs)	DEL	Pathogenic	1679813		GRCh37: X:39913577-39913577 GRCh38: X:40054324-40054324
27	CEBPA	NM_004364.5(CEBPA):c.148G>T (p.Glu50Ter)	SNV	Pathogenic	17567	rs121912791	GRCh37: 19:33793173-33793173 GRCh38: 19:33302267-33302267
28	CEBPA	NM_004364.5(CEBPA):c.251A>T (p.His84Leu)	SNV	Pathogenic	17568	rs28931590	GRCh37: 19:33793070-33793070 GRCh38: 19:33302164-33302164
29	CEBPA	NM_004364.5(CEBPA):c.935_991dup (p.Gln312_Gln330dup)	DUP	Pathogenic	17569	rs1555741948	GRCh37: 19:33792329-33792330 GRCh38: 19:33301423-33301424
30	CEBPA	NM_004364.5(CEBPA):c.925_951dup (p.Glu309_Leu317dup)	DUP	Pathogenic	17570	rs1555741967	GRCh37: 19:33792369-33792370 GRCh38: 19:33301463-33301464
31	CEBPA	NM_004364.5(CEBPA):c.211_214dup (p.Ala72fs)	DUP	Pathogenic	17571	rs587776849	GRCh37: 19:33793106-33793107 GRCh38: 19:33302200-33302201
32	CEBPA	NM_004364.5(CEBPA):c.175G>T (p.Glu59Ter)	SNV	Pathogenic	988408	rs1210600080	GRCh37: 19:33793146-33793146 GRCh38: 19:33302240-33302240
33	CEBPA	NM_004364.5(CEBPA):c.60dup (p.Ser21fs)	DUP	Pathogenic	1067813		GRCh37: 19:33793260-33793261 GRCh38: 19:33302354-33302355
34	CEBPA	NM_004364.5(CEBPA):c.125del (p.Pro42fs)	DEL	Pathogenic	1452019		GRCh37: 19:33793196-33793196 GRCh38: 19:33302290-33302290
35	CEBPA	NM_004364.5(CEBPA):c.69del (p.His24fs)	DEL	Pathogenic	1452838		GRCh37: 19:33793252-33793252 GRCh38: 19:33302346-33302346
36	CEBPA	NM_004364.5(CEBPA):c.332_339del (p.Ala111fs)	DEL	Pathogenic	434688	rs1555742213	GRCh37: 19:33792982-33792989 GRCh38: 19:33302076-33302083
37	CEBPA	NM_004364.5(CEBPA):c.119dup (p.Gln41fs)	DUP	Pathogenic	434686	rs1555742295	GRCh37: 19:33793201-33793202 GRCh38: 19:33302295-33302296
38	FLT3	NM_004119.3(FLT3):c.2520_2521insGGATCC (p.Ser840_Asn841insGlySer)	INSERT	Pathogenic	16271	rs398122514	GRCh37: 13:28592624-28592625 GRCh38: 13:28018487-28018488
39	RUNX1	NM_001754.5(RUNX1):c.588del (p.Val197fs)	DEL	Pathogenic	1013620	rs2057541271	GRCh37: 21:36231796-36231796 GRCh38: 21:34859499-34859499
40	CEBPA	NM_004364.5(CEBPA):c.209del (p.Pro70fs)	DEL	Pathogenic	1698770		GRCh37: 19:33793112-33793112 GRCh38: 19:33302206-33302206
41	GATA2	NM_032638.5(GATA2):c.1084C>T (p.Arg362Ter)	SNV	Pathogenic	435281	rs1553770510	GRCh37: 3:128200721-128200721 GRCh38: 3:128481878-128481878
42	TGM6	NM_198994.3(TGM6):c.1550T>G (p.Leu517Trp)	SNV	Pathogenic	31085	rs387907097	GRCh37: 20:2398091-2398091 GRCh38: 20:2417445-2417445
43	CEBPA	NM_004364.5(CEBPA):c.186_190del (p.Asp63fs)	DEL	Pathogenic	408751	rs1060502121	GRCh37: 19:33793131-33793135 GRCh38: 19:33302225-33302229
44	CEBPA	NM_004364.5(CEBPA):c.168C>A (p.Cys56Ter)	SNV	Pathogenic	850564	rs1967195832	GRCh37: 19:33793153-33793153 GRCh38: 19:33302247-33302247
45	CEBPA	NM_004364.5(CEBPA):c.206del (p.Asp69fs)	DEL	Pathogenic	965859	rs1967194243	GRCh37: 19:33793115-33793115 GRCh38: 19:33302209-33302209
46	RUNX1	NM_001754.5(RUNX1):c.320G>A (p.Arg107His)	SNV	Pathogenic	812740	rs1569084106	GRCh37: 21:36259171-36259171 GRCh38: 21:34886874-34886874
47	KRAS	NM_004985.5(KRAS):c.101C>G (p.Pro34Arg)	SNV	Pathogenic	12590	rs104894366	GRCh37: 12:25398218-25398218 GRCh38: 12:25245284-25245284
48	RUNX1	NM_001754.5(RUNX1):c.161A>T (p.Glu54Val)	SNV	Pathogenic	1701950		GRCh37: 21:36259330-36259330 GRCh38: 21:34887033-34887033
49	RUNX1	NM_001754.5(RUNX1):c.267G>A (p.Leu89_Val90=)	SNV	Pathogenic	1701951		GRCh37: 21:36259224-36259224 GRCh38: 21:34886927-34886927
50	CEBPA	NM_004364.5(CEBPA):c.1039G>A (p.Glu347Lys)	SNV	Pathogenic	1701953		GRCh37: 19:33792282-33792282 GRCh38: 19:33301376-33301376

UniProtKB/Swiss-Prot genetic disease variations for Leukemia, Acute Myeloid:

⁷³

#	Symbol	AA change	Variation ID	SNP ID
1	CEBPA	p.His84Leu	VAR_072677	rs28931590
2	DNMT3A	p.Arg882Cys	VAR_067236	rs377577594
3	DNMT3A	p.Arg882His	VAR_067237	rs147001633
4	JAK2	p.Lys607Asn	VAR_032696	rs121912472
5	JAK2	p.Val617Phe	VAR_032697	rs77375493
6	SETBP1	p.Gly870Ser	VAR_063809	rs267607040
7	SETBP1	p.Ser854Ala	VAR_069848
8	SETBP1	p.Gly870Arg	VAR_069854
9	SETBP1	p.Ile871Ser	VAR_069856	rs267607038

Copy number variations for Leukemia, Acute Myeloid from CNVD:

⁶ (show top 50) (show all 491)

#	CNVD ID	Chromosome	Start	End	Type	Gene Symbol	CNVD Disease
1	13336	1	1	124300000	Insertion		Acute myeloid leukemia
2	13759	1	1	28000000	Deletion		Acute myeloid leukemia
3	14790	1	110122000	110569000	Gain or loss		Acute myeloid leukemia
4	17466	1	142902432	245422360	Duplication		Acute myeloid leukemia
5	18096	1	143961000	247125000	Gain or loss		Acute myeloid leukemia
6	20826	1	154656757	154656845	Amplification		Acute myeloid leukemia
7	24589	1	182359000	182787000	Loss		Acute myeloid leukemia
8	26098	1	197094625	197094734	Amplification		Acute myeloid leukemia
9	26100	1	197094796	197094905	Amplification		Acute myeloid leukemia
10	27263	1	206041820	206041907	Amplification		Acute myeloid leukemia
11	27859	1	214500000	224100000	Deletion		Acute myeloid leukemia
12	28491	1	222606000	222909000	Gain or loss		Acute myeloid leukemia
13	29341	1	230606000	230646000	Gain or loss		Acute myeloid leukemia
14	35033	1	5913000	7696000	Gain or loss		Acute myeloid leukemia
15	35608	1	65296705	65296779	Amplification		Acute myeloid leukemia
16	35769	1	67074000	69951000	Gain or loss		Acute myeloid leukemia
17	36085	1	71305902	71305987	Amplification	MIR186	Acute myeloid leukemia
18	38677	10	104186259	104186331	Deletion		Acute myeloid leukemia
19	38804	10	105144000	105144148	Deletion		Acute myeloid leukemia
20	39144	10	110889374	110889450	Deletion		Acute myeloid leukemia
21	39902	10	122017230	122017301	Deletion	MIRLET7A2	Acute myeloid leukemia
22	41668	10	21893278	22027081	Loss	MLLT10	Acute myeloid leukemia
23	41990	10	27075530	27189965	Translate	ABI1	Acute myeloid leukemia
24	43278	10	46100000	49900000	Copy number	GDF10	Acute myeloid leukemia
25	44445	10	57165247	57165335	Deletion		Acute myeloid leukemia
26	44874	11	64658609	64658718	Deletion	MIR192	Acute myeloid leukemia
27	45369	10	70521000	135283000	Gain		Acute myeloid leukemia
28	47681	10	96486000	100815000	Loss		Acute myeloid leukemia
29	49592	11	108316750	133951370	Triplication		Acute myeloid leukemia
30	50142	11	114500000	121200000	Copy number	KMT2A	Acute myeloid leukemia
31	50190	11	115400000	120700000	Insertion	DDX6	Acute myeloid leukemia
32	50191	11	115400000	120700000	Insertion	ETS1	Acute myeloid leukemia
33	50192	11	115400000	120700000	Insertion	FLI1	Acute myeloid leukemia
34	50193	11	115400000	120700000	Insertion	KMT2A	Acute myeloid leukemia
35	50261	11	116297361	116448564	Loss		Acute myeloid leukemia
36	50346	11	117203762	118563610	Amplification		Acute myeloid leukemia
37	50640	11	118585028	127052111	Deletion		Acute myeloid leukemia
38	51468	11	126537000	130235000	Gain		Acute myeloid leukemia
39	51512	11	127394408	133951311	Amplification		Acute myeloid leukemia
40	52810	11	2016406	2019065	Methylation	H19	Acute myeloid leukemia
41	54217	11	39671000	39746000	Loss		Acute myeloid leukemia
42	54954	11	48161000	49658000	Gain		Acute myeloid leukemia
43	55252	11	50257000	134448000	Gain		Acute myeloid leukemia
44	55325	11	51052000	134450000	Gain		Acute myeloid leukemia
45	55425	11	52900000	134452384	Deletion		Acute myeloid leukemia
46	59078	11	72157700	79025590	Amplification		Acute myeloid leukemia
47	59643	11	76781009	79702160	Duplication		Acute myeloid leukemia
48	59898	11	79188820	117147817	Deletion		Acute myeloid leukemia
49	60046	11	81767896	133951370	Duplication		Acute myeloid leukemia
50	60678	11	89295514	104865304	Triplication		Acute myeloid leukemia

Sources

Expression for Leukemia, Acute Myeloid

Search GEO for disease gene expression data for Leukemia, Acute Myeloid.

Sources

Pathways for Leukemia, Acute Myeloid

Pathways related to Leukemia, Acute Myeloid according to GeneCards Suite gene sharing:

(show all 14)

#	Super pathways	Score	Top Affiliating Genes
1	Disease ⁶⁶ Show member pathways Infectious disease ⁶⁶	13.39	TP53 RUNX1 NUP214 NPM1 KRAS KIT
2	PI3K-Akt signaling pathway ⁷⁴ Show member pathways Focal adhesion: PI3K-Akt-mTOR-signaling pathway ⁷⁴	12.73	TP53 KRAS KIT JAK2 FLT3
3	Overview of interferons-mediated signaling pathway ⁷⁴ Show member pathways all-trans-Retinoic Acid Mediated Apoptosis ⁶⁴ Cytokine Network ⁶⁴ Immune response IFN alpha/beta signaling pathway ²² Interferon alpha/beta signaling ⁶⁶ Jak/STAT Signaling Pathway ⁶⁵ Regulation of IFNA/IFNB signaling ⁶⁶ Type III interferon signaling ⁷⁴	12.38	TP53 TERT KRAS KIT JAK2
4	NF-kappaB Signaling ³	11.87	RUNX1 KIT JAK2 GATA2 CEBPA
5	Gastrin signaling pathway ⁷⁴	11.76	KRAS KIT JAK2
6	Signaling by SCF-KIT ⁶⁶ Show member pathways Regulation of KIT signaling ⁶⁶ Signaling by KIT in disease ⁶⁶ Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants ⁶⁶	11.67	KRAS KIT JAK2
7	Tyrosine Kinases / Adaptors ³	11.63	NPM1 KIT JAK2 FLT3
8	Validated targets of C-MYC transcriptional activation ⁶¹	11.54	TP53 TERT NPM1
9	VEGF Pathway (Tocris) ⁷⁰ Show member pathways Sorafenib Pharmacodynamics ⁶⁰	11.51	KRAS KIT FLT3
10	Head and neck squamous cell carcinoma ⁷⁴	11.44	TP53 TERT KRAS
11	HIF-1-alpha transcription factor network ⁶¹	11.36	GATA2 NPM1 TERT
12	Pathways affected in adenoid cystic carcinoma ⁷⁴	11.29	TP53 NSD1 CEBPA
13	Transcription_Transcription factor Tubby signaling pathways ²²	11.1	TP53 KRAS JAK2
14	Hematopoietic stem cell gene regulation by GABP alpha/beta complex ⁷⁴	10.1	FLT3 ETV6 DNMT3A

Sources

GO Terms for Leukemia, Acute Myeloid

Biological processes related to Leukemia, Acute Myeloid according to GeneCards Suite gene sharing:

(show all 11)

#	Name	GO ID	Score	Top Affiliating Genes
1	cytokine-mediated signaling pathway	GO:0019221	10.06	KIT JAK2 FLT3 CEBPA
2	negative regulation of gene expression	GO:0010629	9.97	GATA2 NPM1 PICALM TERT TP53
3	positive regulation of miRNA transcription	GO:1902895	9.91	TP53 TERT GATA2
4	negative regulation of miRNA maturation	GO:1903799	9.8	TP53 TERT
5	myeloid progenitor cell differentiation	GO:0002318	9.71	KIT FLT3
6	positive regulation of protein localization to nucleolus	GO:1904751	9.62	TERT NPM1
7	regulation of DNA damage response, signal transduction by p53 class mediator	GO:0043516	9.56	TP53 NPM1
8	positive regulation of protein modification process	GO:0031401	9.48	KIT FLT3
9	myeloid cell differentiation	GO:0030099	9.46	JAK2 GATA2 CEBPA
10	hematopoietic stem cell proliferation	GO:0071425	9.43	RUNX1 ETV6 CEBPA
11	hemopoiesis	GO:0030097	9.28	RUNX1 PICALM KIT GATA2 FLT3